Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena Looking To Puff Up Belviq Sales With Smoking Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.

You may also be interested in...

Obesity Market Snapshot: Competition Is Good For Everyone, Especially Orexigen

With more than two years of competition behind them, it’s becoming clear that latecomer Contrave might just be the star of the obesity drug market, while its competitors are stuck playing second fiddle. Yet, all players are benefiting from increased obesity sales reps in the field.

Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience

Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.

Contrave Launch Strategy: Comfortable Drug To Combat Effects Of Comfort Food

Orexigen and marketing partner Takeda’s efforts “will be scaled like a typical diabetes launch,” making it much larger than other recent obesity launches.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts